Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 94

1.

Prognostic factors in pancreatic endocrine neoplasms: an analysis of 136 cases with a proposal for low-grade and intermediate-grade groups.

Hochwald SN, Zee S, Conlon KC, Colleoni R, Louie O, Brennan MF, Klimstra DS.

J Clin Oncol. 2002 Jun 1;20(11):2633-42.

PMID:
12039924
2.

WHO 2004 criteria and CK19 are reliable prognostic markers in pancreatic endocrine tumors.

Schmitt AM, Anlauf M, Rousson V, Schmid S, Kofler A, Riniker F, Bauersfeld J, Barghorn A, Probst-Hensch NM, Moch H, Heitz PU, Kloeppel G, Komminoth P, Perren A.

Am J Surg Pathol. 2007 Nov;31(11):1677-82.

PMID:
18059224
3.

Determining prognosis in patients with pancreatic endocrine neoplasms: can the WHO classification system be simplified?

Ferrone CR, Tang LH, Tomlinson J, Gonen M, Hochwald SN, Brennan MF, Klimstra DS, Allen PJ.

J Clin Oncol. 2007 Dec 10;25(35):5609-15.

PMID:
18065733
4.
5.

Cytokeratin 19 is a powerful predictor of survival in pancreatic endocrine tumors.

Deshpande V, Fernandez-del Castillo C, Muzikansky A, Deshpande A, Zukerberg L, Warshaw AL, Lauwers GY.

Am J Surg Pathol. 2004 Sep;28(9):1145-53.

PMID:
15316313
6.

Proposed histopathologic grading system derived from a study of KIT and CK19 expression in pancreatic endocrine neoplasm.

Zhang L, Lohse CM, Dao LN, Smyrk TC.

Hum Pathol. 2011 Mar;42(3):324-31. doi: 10.1016/j.humpath.2010.09.002. Epub 2010 Dec 28.

PMID:
21190722
7.

Long-term outcomes and prognostic factors in neuroendocrine carcinomas of the pancreas: Morphology matters.

Crippa S, Partelli S, Bassi C, Berardi R, Capelli P, Scarpa A, Zamboni G, Falconi M.

Surgery. 2016 Mar;159(3):862-71. doi: 10.1016/j.surg.2015.09.012.

PMID:
26602841
8.

Mitotic count by phosphohistone H3 immunohistochemical staining predicts survival and improves interobserver reproducibility in well-differentiated neuroendocrine tumors of the pancreas.

Voss SM, Riley MP, Lokhandwala PM, Wang M, Yang Z.

Am J Surg Pathol. 2015 Jan;39(1):13-24. doi: 10.1097/PAS.0000000000000341.

PMID:
25353284
9.

KIT is an independent prognostic marker for pancreatic endocrine tumors: a finding derived from analysis of islet cell differentiation markers.

Zhang L, Smyrk TC, Oliveira AM, Lohse CM, Zhang S, Johnson MR, Lloyd RV.

Am J Surg Pathol. 2009 Oct;33(10):1562-9. doi: 10.1097/PAS.0b013e3181ac675b.

PMID:
19574886
10.

Analysis of risk factors for recurrence after curative resection of well-differentiated pancreatic neuroendocrine tumors based on the new grading classification.

Tsutsumi K, Ohtsuka T, Fujino M, Nakashima H, Aishima S, Ueda J, Takahata S, Nakamura M, Oda Y, Tanaka M.

J Hepatobiliary Pancreat Sci. 2014 Jun;21(6):418-25. doi: 10.1002/jhbp.47. Epub 2013 Oct 20.

PMID:
24142395
11.

Histologic grade, but not SYT-SSX fusion type, is an important prognostic factor in patients with synovial sarcoma: a multicenter, retrospective analysis.

Guillou L, Benhattar J, Bonichon F, Gallagher G, Terrier P, Stauffer E, Somerhausen Nde S, Michels JJ, Jundt G, Vince DR, Taylor S, Genevay M, Collin F, Trassard M, Coindre JM.

J Clin Oncol. 2004 Oct 15;22(20):4040-50. Epub 2004 Sep 13.

PMID:
15364967
12.
13.

Prognostic relevance of survivin in pancreatic endocrine tumors.

Ekeblad S, Lejonklou MH, Stålberg P, Skogseid B.

World J Surg. 2012 Jun;36(6):1411-8. doi: 10.1007/s00268-011-1345-7.

14.

Prognostic factors and survival in 324 patients with pancreatic endocrine tumor treated at a single institution.

Ekeblad S, Skogseid B, Dunder K, Oberg K, Eriksson B.

Clin Cancer Res. 2008 Dec 1;14(23):7798-803. doi: 10.1158/1078-0432.CCR-08-0734.

15.

Prognostic significance of bcl-2, c-myc, survivin and tumor grade in synovial sarcoma.

Demır D, Yaman B, Anacak Y, Keçecı B, Kandıloğlu G, Akalin T.

Turk Patoloji Derg. 2014;30(1):55-65. doi: 10.5146/tjpath.2013.01221.

16.

Survival and prognostic factor analysis in patients with metastatic pancreatic endocrine carcinomas.

Strosberg J, Gardner N, Kvols L.

Pancreas. 2009 Apr;38(3):255-8. doi: 10.1097/MPA.0b013e3181917e4e.

PMID:
19066493
17.

Prognostic factors and survival in endocrine tumor patients: comparison between gastrointestinal and pancreatic localization.

Panzuto F, Nasoni S, Falconi M, Corleto VD, Capurso G, Cassetta S, Di Fonzo M, Tornatore V, Milione M, Angeletti S, Cattaruzza MS, Ziparo V, Bordi C, Pederzoli P, Delle Fave G.

Endocr Relat Cancer. 2005 Dec;12(4):1083-92.

18.

Surgical treatment of pancreatic endocrine neoplasms.

Gomez-Rivera F, Stewart AE, Arnoletti JP, Vickers S, Bland KI, Heslin MJ.

Am J Surg. 2007 Apr;193(4):460-5.

PMID:
17368289
19.

A grading system combining architectural features and mitotic count predicts recurrence in stage I lung adenocarcinoma.

Kadota K, Suzuki K, Kachala SS, Zabor EC, Sima CS, Moreira AL, Yoshizawa A, Riely GJ, Rusch VW, Adusumilli PS, Travis WD.

Mod Pathol. 2012 Aug;25(8):1117-27. doi: 10.1038/modpathol.2012.58. Epub 2012 Apr 13.

20.

Repeat resection of pulmonary metastases in patients with soft-tissue sarcoma.

Weiser MR, Downey RJ, Leung DH, Brennan MF.

J Am Coll Surg. 2000 Aug;191(2):184-90; discussion 190-1.

PMID:
10945362

Supplemental Content

Support Center